Archive: Company News

TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy

— Publication in high-impact Journal of the American Society of Nephrology

— Results pave the way for a novel cell therapy in organ transplantation

TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced 3-year follow-up data of a Phase I trial of its MIC-Lx cell therapy. The results published ahead of print in the Journal of the American Society of Nephrology (doi: 10.1681/ASN.2022020210) indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes.

Read more…

InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer

— Seasoned professional with more than 8 years of healthcare corporate finance experience

InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it has appointed Mrs. Nicole Witzmann as Chief Financial Officer (CFO) effective September 1, 2022.

Read more…

BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants

— Resorbable implants to treat pectus excavatum and silicone breast implant revision / congenital defect correction

— First patients treated in Australia

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced the start of two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia.

Read more…

ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories



HypoxE® Test allows for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) caused by lack of oxygen during birth

— ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers

ELITechGroup and InfanDx AG today announced at the ongoing 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL, USA, the signing of a Memorandum of Understanding (MoU) to collaborate on the development and manufacturing of InfanDx’ HypoxE® Test for ELITechGroup’s family of Selectra Pro clinical chemistry analyzers. The parties intend to enter into a formal collaboration agreement once the biomarkers targeted by InfanDx’ HypoxE® Test are validated in patients from the recently closed BANON cohort study. This final validation is expected by the end of Q3-2022.

Read more…

1 2 143